Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 21 of 277 for:    Non-alcoholic Steatohepatitis | United States

Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02605616
Recruitment Status : Active, not recruiting
First Posted : November 16, 2015
Last Update Posted : July 22, 2019
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Rita Basu, MD, University of Virginia

Brief Summary:
Does the novel drug decrease liver fat in subjects with NASH or NAFLD as compared to placebo

Condition or disease Intervention/treatment Phase
Non-alcoholic Fatty Liver Disease (NAFLD) Non-alcoholic Steatohepatitis (NASH) Drug: AZ compound Other: Placebo Phase 2

Detailed Description:
We propose to combine voxel matched magnetic resonance spectroscopy (MRS) and magnetic resonance elastography (MRE) liver (pre vs. post) to evaluate hepatic fat and hepatic fibrosis. We will also establish glucose tolerance status by our established labeled oral glucose tolerance test (OGTT) (6,6 ²H2 glucose). Following baseline evaluation subjects with biopsy/MRE proven NASH will be randomized to one of two groups and treated either with active drug (AZ compound) or placebo for 12 weeks (plus or minus 1 week). Subjects with history suggestive of non-alcoholic fatty liver disease (NAFLD) or NASH will be invited to participate. If they meet criteria following initial screening they will be included in the study. OGTT, liver MRS, MRE will be repeated. Liver enzymes [aspartate aminotransferase (AST), alanine aminotransferase (ALT),alkaline phosphatase (ALP)] as well as other safety tests [creatine phosphokinase (CPK), thyroid stimulating hormone (TSH), international normalized ratio (INR),total bilirubin] will be measured before, monthly during therapy and at one month following therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blinded, Placebo-controlled Phase IIa Study to Assess the Efficacy and Safety of a Novel AstraZeneca Compound in Subjects With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
Study Start Date : November 2015
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019


Arm Intervention/treatment
Experimental: Active drug AZ compound
AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
Drug: AZ compound
AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).

Placebo Comparator: Placebo
Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
Other: Placebo
Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).




Primary Outcome Measures :
  1. AZD4017 changes hepatic fat as compared to placebo. [ Time Frame: baseline, approximately 12 weeks ]
    AZD4017 changes hepatic fat as compared to placebo.

  2. AZD4017 changes hepatic conversion of [13C] cortisone to [13C] cortisol as compared to placebo. [ Time Frame: baseline, approximately 12 weeks ]
    AZD4017 changes hepatic conversion of [13C] cortisone to [13C] cortisol as compared to placebo.


Secondary Outcome Measures :
  1. Liver fibrosis measured with MRE will be changed in subjects treated with AZD4017 as compared to placebo. [ Time Frame: baseline, approximately 12 weeks ]
    Liver fibrosis will be measured with Magnetic Resonance Enterography (MRE).

  2. Total insulin sensitivity (Si) and hepatic insulin sensitivity (Si liver) will be changed after treatment with AZD4017 than at baseline. [ Time Frame: baseline, approximately 12 weeks ]
    Total insulin sensitivity (Si) and hepatic insulin sensitivity (Si liver) will be measured with OGTT.

  3. Total insulin sensitivity (Si) and hepatic insulin sensitivity (Si liver) will be changed in subjects treated with AZD4017 as compared to placebo. [ Time Frame: baseline, approximately 12 weeks ]
    Total insulin sensitivity (Si) and hepatic insulin sensitivity (Si liver) will be measured with OGTT.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age: 21-75
  • Body Mass Index (BMI) >19 kg/m^2
  • Subjects with biopsy/MRE proven NASH [MRS liver fat ≥ 5%, with elevated liver enzymes ALT <5x upper limit normal (ULN)].
  • Subjects with NAFLD and MRE shows F0 or greater fibrosis
  • Subjects with history suggestive of NAFLD/NASH
  • Total bilirubin must be < 1.5 x ULN and INR must be < 1.3 at baseline screening.
  • TSH and CPK will be within normal limits (WNL) at screening.
  • Subjects with type 2 diabetes who are on stable doses of medications (except pioglitazone) to control hyperglycemia and have baseline HbA1c of 10% or lower.
  • Hemoglobin must be greater than or equal to 12.0 in males and 11.0 in females.

Exclusion Criteria:

  • Medications that may affect glucose metabolism such as corticosteroids, opiates, barbiturates, and anticoagulants.
  • Subjects with anemia, and symptoms suggestive of undiagnosed illness, overt hepatic disease, stroke, Alzheimer's disease, autoimmune hepatitis, alcoholism or increased alcohol consumption over the American Diabetes Association (ADA) guidelines.
  • Any disorder that may potentially impact the outcome measures.
  • Pregnant women and children.
  • Subjects planning weight loss or in any weight loss program.
  • Subjects taking TZD's, Atazanavir, Indinavir, Ketoconazole, Valproic acid, Silybum marianum and Valeriana officinalis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02605616


Locations
Layout table for location information
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
University of Virginia
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Rita Basu, MD University of Virginia

Layout table for additonal information
Responsible Party: Rita Basu, MD, MD, University of Virginia
ClinicalTrials.gov Identifier: NCT02605616     History of Changes
Other Study ID Numbers: 15-000013
First Posted: November 16, 2015    Key Record Dates
Last Update Posted: July 22, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Digestive System Diseases